BCC updated

• The dose-escalation segment of the trial has recently completed
  
• Preliminary data from the dose-escalation segment suggest that the drug candidate appears to be safe and well tolerated and, while some clinical activity was observed, it was less than anticipated
  
• Enrollment in expansion of the “maximum dose group” segment of the trial has been temporarily suspended
  
• Patients are being enrolled in the third segment of the clinical trial, designed to examine the biologic activity of the drug candidate
  
• Curis expects that the trial will be completed in the first half of 2006
  
• At the conclusion of the Phase I trial, Genentech and Curis will make a decision about whether or not to move to a Phase II trial
  

Phase 1 BCC options

If the current drug candidate does not advance into Phase II clinical trials, there are several possible development scenarios including, but not limited to, the following:

• Extend the duration of the treatment regimen of the existing drug candidate (as formulated)
  
• Reformulate the current drug candidate for a new Phase I trial with a topical formulation
  
• Use one of the additional compounds licensed to Genentech for a new Phase I trial with a topical formulation
  
• Return the compounds to Curis for internal development
  
• Cease the BCC program all together, but maintain the other programs for solid tumors and the undisclosed pathway

Download complete article
Company_Presentation_1.23.06.ppt

Curis to Present at the Brean Murray Small Cap Institutional Investor Conference

CAMBRIDGE, Mass., Jan 26, 2006 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that the Company will be presenting at the Brean Murray Small Cap Institutional Investor Conference on Wednesday, February 1st, at the Grand Hyatt Hotel in New York City.

Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 12:30 p.m. Eastern. There will be a webcast of the presentation at:

http://www.wsw.com/webcast/bmry2/cris/

The presentation will be archived shortly after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.

Press Releases

Curis to Present at the BIO CEO & Investor Conference 2006
CAMBRIDGE, Mass., Feb 08, 2006 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that the Company will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14th, at the Waldorf-Astoria Hotel in New York City.

Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 2:30 p.m. Eastern. There will be a webcast of the presentation at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CRIS&item_id=1210818

The presentation will be archived shortly after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.

About Curis, Inc.

Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under two collaborations with Genentech, one of which includes a co-development arrangement for a basal cell carcinoma product candidate that is currently in a Phase I clinical trials), neurological disorders (under collaboration with Wyeth), hair growth (under collaboration with Procter & Gamble), kidney and other diseases (licensed to Ortho Biotech Products and under development at Centocor, both subsidiaries of Johnson & Johnson), and cardiovascular disease. Curis also possesses robust small molecule drug screening technologies and preclinical scientific expertise that Curis believes it can use to create a sustainable drug candidate pipeline including, for example, its Spinal Muscular Atrophy research program (under sponsored research agreement with the Spinal Muscular Atrophy Foundation). For more information, please visit the Curis web site at www.curis.com.

SOURCE: Curis, Inc.

For Curis, Inc.
Michael P. Gray, 617-503-6632
Chief Financial Officer
or
Megan Burns, 617-503-6658
Director, Corporate Communications

Business Model
Collaborations and Product Candidates
Patents/Financials



Corporate_Presentation_Feb_2006.ppt

Curis to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
CAMBRIDGE, Mass., Mar 27, 2006 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that the Company will be presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, April 5th, at the Millennium Broadway Hotel in New York City.

Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 10:00 a.m. Eastern. There will be a webcast of the presentation at:

http://www.veracast.com/webcasts/cibcwm/biotech06/87204312.cfm

The presentation will be archived shortly after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.

Curis files amended 10-Q


http://www.sec.gov/Archives/edgar/data/1108205/000119312506070143/d10qa.htm

Any thoughts?

Curis Announces Hedgehog Antagonist Data Presentation at AACR
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 3, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced the presentation of data at the 97th Annual Meeting of the American Association for Cancer Research (AACR). The preclinical animal model data presented suggested that a Hedgehog antagonist inhibited the growth of tumors in pancreatic cancer and small cell lung cancer. The data are being presented by a Genentech, Inc. researcher as part of the "New Horizons in the Development of Targeted Therapies for the Treatment of Cancer" Symposium. These data were generated as part of Curis' ongoing collaboration with Genentech to develop systemically administered Hedgehog small molecule antagonists for the potential treatment of solid tumors.

The presentation at the AACR described the use of a Hedgehog antagonist in small cell lung and pancreatic cancers, diseases that both have very low survival rates. For these studies, researchers used a primary tumor xenograft model, whereby a human tumor is grown and expanded directly in recipient mice. Treatment with a small molecule Hedgehog antagonist inhibited the rate of tumor growth in mouse xenograft models initiated from both a human small cell lung cancer and a human pancreatic cancer.

"We are pleased with the data presented today, which showed that a Hedgehog antagonist slowed tumor growth in preclinical models of these deadly cancers," said Daniel R. Passeri, President and Chief Executive Officer.

Curis also presented two posters on the Hedgehog pathway and its role in two other cancers, basal cell carcinoma (BCC) and medulloblastoma, a rare childhood brain cancer.

The American Cancer Society predicts that, in 2006, about 33,730 people in the United States will be found to have pancreatic cancer and about 32,300 will die of the disease. This kind of cancer is the fourth leading cause of cancer death. About 1 out of 4 patients with cancer of the exocrine pancreas will live at least 1 year after the cancer is found. Only about 1 in 25 will survive for 5 years or more. According to the American Cancer Society, in 2006 there will be about 174,470 new cases of lung cancer (both small cell and non-small cell) in the United States. About 162,460 people will die of this disease. About 6 out of 10 people with lung cancer die within 1 year of finding out they have lung cancer. Between 7 and 8 will die within 2 years.

link

This means we have a better picture what the future IND's might be. I'm a little suprised that they didn't talk about prostate cancer... See IND link for a complete list of Hh related cancers.

Genentech Funds Additional Hedgehog Research at Curis; Update on Phase I Basal Cell Carcinoma Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2006--Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today announced that Genentech has extended funding to support Curis personnel performing research services through December 2006, with an option to extend further research funding through June 11, 2007, if both parties agree. It is currently expected that Curis personnel would support the two companies' ongoing research in the systemic Hedgehog antagonist program and development of xenograft models for use in other Genentech programs. Under the terms of the amendment that extends funding, these researchers could also support efforts on other collaborative programs between the two companies.

Genentech and Curis have done extensive preclinical work on orally bioavailable small molecule Hedgehog antagonists and continue to conduct studies to support possible future clinical testing of these molecules. Genentech is currently conducting preclinical studies that may support an Investigational New Drug (IND) application for this drug candidate for future clinical testing.

As part of this collaboration, a Phase I study of a small molecule antagonist of the Hedgehog pathway in basal cell carcinoma is currently ongoing. This is a double-blind, randomized, placebo-controlled study that began enrolling patients in the second quarter of 2005. The primary objective of this study is to obtain data about the preliminary safety and tolerability profile of a four-week regimen of the drug candidate. In addition, the companies will evaluate the clinical activity of the drug candidate, defining clinical activity as the complete eradication of the treated basal cell carcinoma lesion, which is determined by clinical and microscopic examinations of the lesions.

This study is enrolling a total of approximately 60 patients over three segments:

-- Segment 1, a dose-escalation segment in which patients are
randomized to receive treatment at one of four dose levels

-- Segment 2, a segment in which additional patients are treated
at the highest dose from the dose-escalation segment (Segment
1)

-- Segment 3, a pharmacodynamic segment to evaluate biologic
activity of the molecule

As previously announced, preliminary data from Segments 1 and 2 revealed no significant safety concerns and suggested some signs of activity, although there was less clinical activity observed than anticipated. Final data from all three segments is planned to be unblinded and analyzed in late 2006; Curis originally anticipated that data would be available in June 2006.

"Having data from all three segments will help to provide the information necessary to determine the activity of the molecule, as well as the validity of the target." said Daniel R. Passeri, President and Chief Executive Officer of Curis, Inc.

Curis Initiates Strategic Plan Focused on Later-Stage Drug Development; Recognized Leader in Drug Development, Dr. Joseph Davie, to Lead Curis' New Scientific Advisory Board and Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 8, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced the initiation of a new strategic focus on seeking to develop later-stage drug development programs and to de-emphasize its earlier-stage discovery research. This new direction represents an expansion of Curis' continuing strategy to mitigate risk by seeking to both create and acquire a broad portfolio of later-developmental stage assets and maximize the Company's capacity and competencies in drug development. In addition to furthering our internal development candidates, Curis will continue to evaluate in-licensing opportunities to augment the Company's proprietary later stage preclinical pipeline.

Daniel R. Passeri, President and Chief Executive Officer of Curis, Inc., stated, "As Curis executes on its efforts to move closer to the clinic with its preclinical drug candidates, over the next year, we intend to shift our strategic focus away from early-stage discovery research into later-preclinical stage drug development. As part of this transition and aligned with this strategy, Dr. Lee Rubin, our Executive Vice President and Chief Scientific Officer, will step down as Curis' CSO, having accepted a position at the Harvard University Stem Cell Institute. We expect Dr. Rubin to continue his involvement with the Company as a scientific consultant. Our current board member, Dr. Joseph Davie, will serve as interim Chief Scientific Officer and will temporarily oversee Curis' drug programs while also assisting Curis in its efforts to build a more development-focused scientific team."

Dr. Davie has served on the Curis board since July 2003. From 1993 to 2000, he was the Senior Vice President of Research at Biogen, Inc., now Biogen Idec. Prior to joining Biogen, Dr. Davie held several senior positions at G.D. Searle and Co., including Senior Vice President of Science and Technology and President of Research and Development. Dr. Davie serves on the boards of several public and private biotechnology companies. He received his M.D. from the Washington University School of Medicine and his Ph.D. from Indiana University.

Mr. Passeri continued, "Dr. Davie has also agreed to serve as the new Chairman of Curis' Scientific Advisory Board. Over the coming months, we expect that Dr. Davie will build a Scientific Advisory Board that is comprised of members with late-stage preclinical and clinical stage drug development experience in a variety of disease areas including cancer, dermatology and neurology.

"We would like to thank Dr. Rubin for his years of service to Curis and the leadership he has shown throughout his tenure here."

Joseph M. Davie, MD, Ph.D., Interim Chief Scientific Officer of Curis, Inc., stated, "I am delighted to take on these new roles at Curis and I look forward to helping the Company smoothly transition into its next phase of development. During my tenure as a Curis Board member, I have been impressed with the potential applications of the Hedgehog pathway and with the significant collaborations that Curis has initiated, including those with Genentech, Wyeth and Procter & Gamble. I look forward to working with Dan and the rest of the Curis team to help maximize the value of Curis' existing drug programs under collaboration and to assist in the development of additional proprietary drug programs."

Does moving foward wit pre-clinical projects mean the hairloss Hh agonist?

My take on it was that their discovery research was going to be de-emphasized and would probably have no effect on the hair program. Note sure if anybody has been reading the headlines about starting more stem cell research by harvard. One of the main leaders name is "Douglas Melton", Douglas Melton co-founded curis.

The next part of the headlines state


Rubin is leaving Curis to go help his friend Douglas Melton. As a consequence curis will not be working as much on stem cells. This will allow their team to focus on bringing stuff into the clinic.

My take on it was that their discovery research was going to be de-emphasized and would probably have no effect on the hair program. Note sure if anybody has been reading the headlines about starting more stem cell research by harvard. One of the main leaders name is "Douglas Melton", Douglas Melton co-founded curis.

The next part of the headlines state


Rubin is leaving Curis to go help his friend Douglas Melton. As a consequence curis will not be working as much on stem cells. This will allow their team to focus on bringing stuff into the clinic.

Curis Issued U.S. Patent Covering Drug Discovery Assays
Tuesday June 13, 9:00 am ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 13, 2006--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today announced the receipt of U.S. patent number 7,060,450, which covers screening assays for antagonists and agonists of the Hedgehog signaling pathway. This patent includes cell-based assays that use a Hedgehog responsive promoter element containing Gli binding sites as the read-out. Gli expression levels are important in identifying potential Hedgehog pathway targeted drug candidates since Gli levels are higher when the Hedgehog pathway is turned on, or agonized, and lower when Hedgehog signaling is inhibited, or antagonized. Further, because these assays report on the final step of Hedgehog pathway activation, they are effective in identifying compounds that modulate Hedgehog signaling at virtually any point in the signaling pathway.


Curis has used its knowledge of the Hedgehog pathway to create drug discovery assays that have produced drug targets for the treatment of a variety of diseases such as cancer and stroke. As part of its collaboration with Genentech, Curis has discovered Hedgehog antagonists that are being studied for the systemic treatment of solid tumors as well as a topical antagonist for the treatment of basal cell carcinoma, currently in a Phase I trial. With Wyeth, Curis is working on the development of orally available Hedgehog agonists for the treatment of stroke and other neurological disorders and with Procter & Gamble, the Company is working on the development of topical Hedgehog agonists for male pattern baldness and female pattern hair loss.

"Protecting and enhancing our patent estate has always been a priority for Curis," said Daniel R. Passeri, President and CEO of Curis, Inc. "With our broad patent portfolio, we believe that we own the seminal intellectual property covering the Hedgehog pathway and its uses for the treatment of a variety of diseases and disorders. With this new patent, we believe that we can further insure that we have the proprietary technology to develop assays that will allow us to develop novel small molecule treatments in oncology, dermatology, neurology and other disease areas."

NEW YORK, Sept 1 (Reuters) - Curis Inc. (CRIS.O: Quote, Profile, Research) on Friday said it was terminating its spinal muscular atrophy discovery-stage research program, moving its focus to later-stage development of drug candidates.

Curis also said it was ceasing participation with Genentech (DNA.N: Quote, Profile, Research) in the co-development of a basal cell carcinoma drug candidate. The parties previously announced they were halting enrollment in a Phase I clinical trial.
Ref